Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide’s fully diluted share capital (excluding therefrom any treasury shares) at…Read More
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
